DOCSLIB.ORG

JULY 2008 World Neurology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
JULY 2008 World Neurology VOL. 23 • NO. 2 • JULY 2008 World Neurology THE OFFICIAL NEWSLETTER OF THE WORLD FEDERATION OF NEUROLOGY Welcome to the New WORLD NEUROLOGY! INSIDE From Germany: tarting with this is- scientific advances. What view of a brief, little-known top- As the German sue, WORLD NEUROL- interests you may well in- ic of interest in clinical neurolo- Society for Neurology SOGY will have new terest others. gy. The first installment is on turns 100, a look content and a new look. As In this inaugural issue, the Ramsay Hunt syndromes. back on the history the newsletter of the World you will find some new fea- Can you describe all four with- of the specialty in Federation of Neurology tures. One of these is “Pro- out cheating? Deutschland. PAGE 8 (WFN), WORLD NEUROLO- files in Neurology.” In it, I We also will publish cases. GY is the only publication hope to spotlight different Some of these may be disorders going to all neurologists in medical care practices from that are seen only in certain parts the world. around the world, giving of the world or that are more The newsletter will con- one neurologist his or her common in particular places. From Brazil: tinue to feature news from chance at “fifteen minutes Others may be rare but important EWS A case series of N the WFN. However, the of fame,” as the expression to keep in mind. So send in your dengue fever shows new version will have other goes. I am grateful to Dr. suggestions! EDICAL why neurologists content of interest to neu- M Rawiphan Witoonpanich We expect that cases, as well as should be wary rologists, including some of Mahidol University, the other articles, will be illus- LOBAL of this infectious neurology news, and will G Bangkok (Thailand), for trated with photographs or oth- disease. PAGE 10 be published by Elsevier. starring in the first of er images—an interesting MRI, LSEVIER We are all grateful to Prof. E these. for example. And with all articles, Jagjit Chopra, who has New WORLD NEUROLOGY editor in chief Dr. We’re also interested in we will want to have a photo- done a spectacular job of Mark Hallett plans to revamp the newsletter. news from the National So- graph of you, too. editing WORLD NEUROLOGY cieties that make up the WORLD NEUROLOGY should be a From Thailand: for the past decade. Neurophysiology. Presently, I WFN. For example, the German useful and educational newsletter. Dr. Rawiphan So who am I? I am a neurolo- served as an associate editor for Society just celebrated its 100th Send your feedback and ideas to Witoonpanich gist at the National Institute of the journal Brain as well as for a anniversary. In this issue, Dr. [email protected]. writes about her Neurological Disorders and new journal, Brain Stimulation. Günther Deuschl and his col- Let’s keep each other informed practice in Thailand, Stroke, at the National Institutes Although I hope to assemble leagues present a brief history of and knowledgeable, so we can home of the 2009 of Health in Bethesda, Md., an editorial board to help me in the society. We will highlight oth- bring good neurologic practice to World Congress on where I do clinical research. My the coming months, as the new er national societies in upcoming our patients and have some fun Neurology. PAGE 12 interests are clinical neurophysi- medical editor, I will be looking issues. along the way. ology and movement disorders. I for input from everyone. So This issue also includes the Mark Hallett recently completed an 8-year please send in local news, or first “Neurologic Pearl.” This Editor in Chief term as editor in chief of Clinical news of interesting medical and column will give an in-depth World Neurology Oral Agent for Form of Multiple Sclerosis Shows Promise BY DOUG BRUNK Comi of the institute of experi- terview, “This is a first step in the study was the mean cumulative surprised the researchers, con- Elsevier Global Medical News mental neurology at the Vita- direction of identifying a therapy number of GdE lesions per scan sidering that the 0.3-mg dose Salute San Raffaele University, for use early in the course of mul- in the last four scans. demonstrated efficacy, compared atients with relapsing remit- Milan. tiple sclerosis which is convenient, The researchers reported that with placebo, in a previous study Pting multiple sclerosis who Developed by Teva Pharma- safe, and effective. Whether oral patients in the laquinimod 0.6 (Neurology 2005;64:987-91). took daily oral laquinimod over a ceutical Industries Ltd., laquini- laquinimod meets these charac- mg daily group demonstrated a One possible explanation could 36-week period achieved a 40% mod is an oral immunomodula- teristics remains to be seen.” 40% reduction in the mean num- be that the previous study used a reduction in gadolin- tory drug that is In a study conducted at 51 cen- ber of GdE lesions over the last triple dose of gadolinium, “which ium-enhancing le- believed to exert anti- ters in nine countries, Dr. Comi four scans, compared with those increases the harvest of active sions compared with inflammatory activity and his associates randomized in the placebo group (a mean of multiple sclerosis lesions by 60%, patients who took in the relapsing re- 102 patients with relapsing re- 2.6 vs 4.2, respectively). Patients and, as a consequence, increases placebo, according to mitting form of MS mitting multiple sclerosis to in the laquinimod 0.3 mg daily the statistical power of MRI- phase II trial results. by the Th1-Th2 shift. placebo, 98 to laquinimod 0.3 mg group had a mean number of monitored trials,” the researchers “Overall, the effi- To date, approved daily, and 106 to laquinimod 0.6 GdE lesions similar to the place- cacy and safety pro- drugs for MS are all mg daily for 36 weeks (Lancet bo group (3.9). The latter finding See Multiple Sclerosis • page 2 file emerging from injectable and in- 2008;37:2085-92). this and from a pre- clude glatiramer ac- Patients were aged 18-50 years vious phase II clini- DR. GIANCARLO etate, interferon-β, and underwent brain MRI and cal trial, in combina- COMI natalizumab, and mi- clinical assessments 4 weeks be- tion with the oral toxantrone. fore the study started, at baseline, route of administration, make Prof. Alastair Compston, head and then every 4 weeks for 9 laquinimod a promising thera- of the department of Clinical months. The researchers mea- peutic opportunity for patients Neurosciences at the University sured the number of gadolinium- with relapse remitting multiple of Cambridge (England), who enhancing (GdE) lesions at weeks sclerosis,” reported the re- was unaffiliated with the study, 12, 16, 20, 24, 28, 32, and 36. searchers, led by Dr. Giancarlo told WORLD NEUROLOGY in an in- The primary end point of the 2 • WORLD NEUROLOGY WWW.WFNEUROLOGY.ORG • JULY 2008 GdE Lesions In an accompanying editorial, Dr. B. Mark New Editor in Chief Keegan and Dr. Brian G. Weinshenker of the Fell 40% department of neurology at the Mayo Clinic, Mark Hallett Takes Over Rochester, Minn., noted that many patients Multiple Sclerosis • from page 1 would prefer an oral medication such as he process of reformatting world. WORLD NEUROLOGY will explained. “GdE lesions visible only on triple- laquinimod and recommended that a head-to- WORLD NEUROLOGY is over, serve as a support mechanism to a dose scans are usually smaller and with a less- head analysis of the drug with existing im- Tand the inaugural issue, which sense of solidarity, of knowing what severe blood-brain barrier dysfunction than munomodulatory medications be conducted you now hold in your hand, is the is going on in neurology every- those enhanced after a standard dose.” (Lancet 2008;37:2059-60). They also called for new link that will connect neurolo- where. The current trial used a standard dose of careful investigations of safety, “because seri- gists all over the world. Therefore, WORLD NEUROLOGY gadolinium. Until the Chinese Society of Neu- will provide information about cur- In terms of safety, two adverse events po- rology joined the World Federation of rent developments in modern neu- tentially attributable to laquinimod occurred. THIS IS THE FIRST STEP Neurology last year, we served a rology, with dissemination of thera- One patient in the laquinimod 0.6 mg daily TOWARD DEVELOPING A membership of about 25,000. peutic advances and discussions on group had Budd-Chiari syndrome and was That number is now considerably hot topics in the neurologic com- found be heterozygous for the factor V Leiden CONVENIENT, SAFE, AND EFFECTIVE higher, and I am proud to say that the munity. mutation, “which is associated with up to THERAPY FOR MS. We are delighted to have Mark 30% of cases of venous thrombosis,” the re- Hallett as our new editor in chief. searchers noted. “This case highlighted the THE NEWSLETTER’S Because he was the chair of the fi- possibility of an increased risk for thrombosis ous adverse effects are commonly not evident nance committee until he took over in patients with pre-existing thrombophilia until phase II studies are started (as with lino- FUNCTION IS TO CONVEY his new position, Mark Hallett exposed to laquinimod, which needs to be fur- mide) or until after approval (as with natal- INFORMATION FROM AND TO knows the World Federation of ther explored.” izumab).” WFN’S CENTRAL Neurology very well. Dr. Hallett did One patient in the laquinimod 0.3 mg daily Teva Pharmaceuticals sponsored and fund- his neurology training at Massachu- group had persistent elevation in liver enzymes ed the study.
Load more

Recommended publications
  • Neurological Sciences LE JOURNAL CANADIEN DES Sciences Neurologiques
    Volume 26 Number 4 November 1999 THE CANADIAN JOURNAL OF Neurological Sciences LE JOURNAL CANADIEN DES Sciences Neurologiques AN INTERNATIONAL JOURNAL / UN JOURNAL INTERNATIONAL REVIEW ARTICLE 255 EEG in Epilepsy: Current Perspectives M. Sundaram, R.M. Sadler, G.B. Young and N. Pillay ORIGINAL ARTICLES 263 Burden of Epilepsy: The Ontario Health Survey Samuel Wiebe, David R. Bellhouse, Christine Fallahay, Michael Eliasziw 271 Topiramate in Intractable Childhood Onset Epilepsy - A Cautionary Note J.M. Dooley, P.R. Cornfield, E. Smith, P. Langevin, G. Ronen 21A Consensus Statement of the Canadian MS Clinics Network on: The Use of Disease Modifying Agents in Multiple Sclerosis Joel Oger and Mark Freedman Dr. Charles G. Drake 1920-1998 276 Treatment with Interferon Beta- lb Improves Quality of Life in Multiple Sclerosis G.P. Rice, J. Oger, P. Duquette, G.S. Francis, M. Belanger, S. Laplante, J.F. Grenier 283 Responsiveness of the Scripps Neurologic Rating Scale During a Multiple Sclerosis Clinical Trial James A. Koziol, Adridna Lucero, Jack C. Sipe, John S. Romine, Ernest Beutler 290 MR Characteristics of Malignant Spinal Cord Astrocytomas in Children Abhaya V. Kulkarni, Derek C. Armstrong and James M. Drake 294 EMG Related Anxiety and Pain: A Prospective Study Mohammed M.S. Jan, Murray Schwartz, and Timothy J. Benstead EXPERIMENTAL NEUROSCIENCES 298 Biphasic Opening of the Blood-Brain Barrier Following Transient Focal Ischemia: Effects of Hypothermia Z. Gao Huang, Dong Xue, Edward Preston, Hasneen Karbalai, Alastair M. Buchan 305 Mevalonate Prevents Lovastatin-Induced Apoptosis in Medulloblastoma Cell Lines Wei Wang and Robert J.B. Macaulay Neuroimaging Highlight NEUROIMAGING HIGHLIGHT 311 Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) J.N.
    [Show full text]
  • Revista Română De Cardiologie
    REVISTA ROMÂNĂ DE CARDIOLOGIE ROMANIAN HEART JOURNAL Vol. XXI, Nr. 2, 2006 REVISTA ROMÂNĂ DE CARDIOLOGIE REVISTA SOCIETĂŢII ROMÂNE DE CARDIOLOGIE COLECTIVUL DE REDACŢIE Redactor șef: Redactor șef adjunct: Prof. Dr. Eduard Apetrei Prof. Dr. Carmen Ginghină Redactori: Redactori asociaţi: Prof. Dr. Radu Căpâlneanu Dr. Mihaela Rugină Prof. Dr. Cezar Macarie Dr. Ruxandra Jurcuţ Dr. Bogdan A. Popescu Dr. Costel Matei Redactor fondator Prof. Dr. C. Carp Colegiul de redacţie: Prof. Dr. E. Grosu – R. Moldova Prof. Dr. Ion V. Bruckner – București Prof. Dr. Alexandru Ioan – București Prof. Dr. Alexandru Câmpeanu – București Prof. Dr. Dan Dominic lonescu – Craiova Prof. Dr. Mircea Cinteză – București Dr. Matei Iliescu – București Dr. Radu Ciudin – București Prof. Dr. Ioan Maniţiu – Sibiu Prof. Dr. Radu Cristodorescu – Timișoara Prof. Dr. Gerald A. Maurer – Austria Prof. Dr. D.V. Cokinos – Grecia Dr. Șerban Mihăileanu – Franţa Dr. Dan Deleanu – București Prof. Dr. Nour Olinic – Cluj Napoca Prof. Dr. Genevieve Derumeaux – Franţa Prof. Dr. Fausto Pinto – Portugalia Prof. Dr. Doina Dimulescu – București Prof. Dr. Mariana Rădoi – Brașov Prof. Dr. Maria Dorobanţu – București Prof. Dr. Willem J. Remme – Olanda Prof. Dr. Ștefan Iosif Drăgulescu – Timișoara Dr. Doina Rogozea – București Prof. Dr. Guy Fontaine – Franţa Prof. Dr. Michal Tendera – Polonia Prof. Dr. Bradu Fotiade – București Prof. Dr. Ion Ţintoiu – București Prof. Dr. Alan Fraser – Anglia Prof. Dr. Panagiotis Vardas – Grecia Prof. Dr. Mihai Gheorghiade – USA Conf. Dr. Dragoș Vinereanu – București Prof. Dr. George Georgescu – Iași Prof. Dr. Marius Vintilă – București Prof. Dr. Leonida Gherasim – București Prof. Dr. Dumitru Zdrenghea – Cluj Napoca Redactor de număr: Dr. Mihaela Rugină 84 CUPRINS VOL. XXI, nr.
    [Show full text]
  • On the Front Lines of Mental Health
    WINTER 2014 UNIVERSITY OF TORONTO MEDICAL ALUMNI ASSOCIATION MAGAZINE MAAMATTERS ON THE FRONT LINES OF MENTAL HEALTH ConvoCation 2014 • FivE DECaDES DiFFEREnt? TO COME DEAN’S MESSAGE Dr. CaTharine WhiTesiDe (1975) A farewell message The Medical Alumni Association (MAA) to provide opportunities to help build at the University of Toronto is one of our and sustain this valued relationship. most important organizations for the When students and trainees enter our ongoing and future success of our medical MD and postgraduate programs, we school. As I complete my tenure as the welcome them into the U of T medical Dean of Medicine and look back over my school family and make a tremendous years closely associated with the MAA, I am effort enabling them to fulfill their HY P very proud of the dedication and accom- potential. Once they graduate they should RA G plishments of our alumni and the MAA feel part of our extended family that now Board. Last year the Faculty established reaches into every aspect of the Canadian PHOTO L E three alumni awards, including the Alumni health system and beyond. We must NN O D Volunteer Award, the Lifetime Achievement provide support for their continuing Award and the Rising Star Award. The professional development, access to rapidly HY: MAC HY: P MAA also recognizes alumni contributions expanding knowledge and its application, RA G through awards and scholarships. and we must welcome their engagement It is so important that we recognize in the mentoring and teaching of our PHOTO alumni who have made an impact through students and trainees.
    [Show full text]
  • Killam Prizes | Prix Killam
    Killam Prizes | Prix Killam Year | Winners | University | Discipline Année Gagnants Université 2021 Michel Bouvier Université de Montréal Health Sciences | sciences de la santé Stephen R. Gill York University Social Sciences | sciences sociales Gilbert Laporte HEC Montréal Engineering | génie Arthur Ripstein University of Toronto Humanities | sciences humaines Douglas Stephan University of Toronto Natural Sciences | sciences de la nature 2020 Cecilia Benoit University of Victoria Social Sciences | sciences sociales Sarah Carter University of Alberta Humanities | sciences humaines Alan Evans Montreal Neurological Institute Health Sciences | sciences de la santé Ted Sargent University of Toronto Engineering | génie Barbara Sherwood Lollar University of Toronto Natural Sciences | sciences de la nature 2019 Yoshua Bengio Université de Montréal Natural Sciences | sciences de la nature André Blais Université de Montréal Social Sciences | sciences sociales Keith W. Hipel University of Waterloo Engineering | génie Stephen W. Scherer University of Toronto Health Sciences | sciences de la santé Lynne Viola University of Toronto Humanities | sciences humaines 2018 André Gaudreault Université de Montréal Humanities | sciences humaines Vladimir Hachinski Western University Health Sciences | sciences de la santé Walter Herzog University of Calgary Engineering | génie James Pinfold University of Alberta Natural Sciences | sciences de la nature Janet Werker University of British Columbia Social Sciences | sciences sociales Canada Council for the Arts
    [Show full text]
  • News Release
    NEWS RELEASE: June 14, 2005 Health care leaders create Canada’s first national health advisory body The Canadian Academy of Health Sciences will give Government and the public comprehensive expertise and advice on health issues EDMONTON - When the President of the United States wants advice on a public health issue, he calls the United States’ National Academies. When the Prime Minister of Great Britain wants to seek similar counsel, he usually turns to the Royal Society of Britain. But when the Prime Minister of Canada wants similar advice, who does he call? Well, that’s not always entirely clear, given the more narrowly defined mandates of many Canadian organizations. Now, however, owing to a recent initiative by a group of leading health care leaders and researchers, the Prime Minister will be able to call the Canadian Academy of Health Sciences (CAHS), recently created to: • Develop informed, strategic assessments on urgent health issues; • Inform public policy on these issues; • Enhance Canada’s readiness to deal with global health issues; and, • Provide a recognized and authoritative Canadian health science voice internationally. According to one of the Academy’s key organizers, the establishment of the Academy is long over due—and all the more pressing given the potential global health threats to Canadians, most recently exemplified by the SARS threat. “Ask Canadians what they care about most, and they answer unequivocally: ‘health,’” explains University of Alberta Professor of Medicine Paul Armstrong, CAHS’s first president. “It makes sense, therefore, that Canada should have an organization that government—and Canadians—can turn to for sound, impartial advice and research on pressing health issues.” The organization will also have an international role to play, representing Canada’s interests abroad and working closely with other nations’ parallel agencies.
    [Show full text]
  • Neuroscience in Nazi Europe Part II: Resistance Against the Third Reich Lawrence A
    HISTORICAL REVIEW Neuroscience in Nazi Europe Part II: Resistance against the Third Reich Lawrence A. Zeidman ABSTRACT: Previously, I mentioned that not all neuroscientists collaborated with the Nazis, who from 1933 to 1945 tried to eliminate neurologic and psychiatric disease from the gene pool. Oskar and Cécile Vogt openly resisted and courageous ly protested against the Nazi regime and its policies, and have been discussed previously in the neurology literature. Here I discuss Alexander Mitscherlich, Haakon Saethre, Walther Spielmeyer, Jules Tinel, and Johannes Pompe. Other neuroscientists had ambivalent roles, including Hans Creutzfeldt, who has been discussed previously. Here, I discuss Max Nonne, Karl Bonhoeffer, and Oswald Bumke. The neuroscientists who resisted had different backgrounds and moti vations that likely influenced their behavior, but this group undoubtedly saved lives of colleagues, friends, and patients, or at least prevented forced sterilizations. By recognizing and understanding the actions of these heroes of neuroscience, we pay homage and realize how ethics and morals do not need to be compromised even in dark times. RÉSUMÉ: Neuroscience en Europe sous domination nazie, 2e partie : résistance contre le Troisième Reich. J’ai mentionné antéri eurement que tous les neuroscientifiques n’avaient pas collaboré avec les nazis qui, de 1933 à 1945, ont tenté d’éliminer la maladie neurologique et psychiatrique du patrimoine génétique. Oskar et Cécile Vogt se sont opposés ouvertement et ont protesté courageusement contre le régime nazi et ses politiques. Ce sujet a déjà été exposé dans la littérature neurologique. Je discute ici d’Alexander Mitscherlich, de Haakon Saethre, de Walther Spielmeyer, de Jules Tinel et de Johannes Pompe.
    [Show full text]
  • Concomitant Vascular and Neurodegenerative Pathologies Double the Risk of Dementia
    Alzheimer’s & Dementia - (2017) 1-9 Featured Article Concomitant vascular and neurodegenerative pathologies double the risk of dementia Mahmoud Reza Azarpazhooha,b,c,1, Abolfazl Avanb,d,1, Lauren E. Ciprianoc,e, David G. Munozf, Luciano A. Sposatoa,c,g,h, Vladimir Hachinskia,c,* aDepartment of Clinical Neurological Sciences, Western University, London, Ontario, Canada bDepartment of Neurology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran cDepartment of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada dDepartment of Neurology, Academic Medical Center, Amsterdam, The Netherlands eIvey Business School, Western University, London, Ontario, Canada fDepartment of Pathology and Laboratory Medicine, University of Toronto & Department of Laboratory Medicine, and Keenan Research Centre for Biomedical Research, The Li Ka Shing Knowledge Institute, St Michael’s Hospital Toronto, Ontario, Canada gStroke, Dementia and Heart Disease Laboratory, Western University, London, Ontario, Canada hDepartment of Anatomy & Cell Biology, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada Abstract Introduction: The relative contributions of vascular and degenerative pathology to dementia are un- known. We aim to quantify the proportion of dementia explained by potentially preventable vascular lesions. Methods: We systematically searched for population-based cohorts before February 2017 reporting clinicopathological data for individuals with and without dementia. We calculated the summary pro- portion and absolute risk of dementia comparing subjects with and without the pathology. Results: We identified 10 studies comprising 2856 subjects. Vascular-type pathology and mixed pa- thology are respectively two and three times more likely in demented patients. The summary propor- tion of dementia is 77%–86% in subjects with mixed degenerative and vascular pathology and 45% in subjects with pure Alzheimer-type pathology.
    [Show full text]
  • International Innovation Professor Vladimir Hachinski
    A stroke of genius With over 600 scholarly articles and 23,000 citations to his name, Professor Vladimir Hachinski has been at the forefront of stroke, sudden death and vascular cognitive impairment research for the last 40 years PROFESSOR VLADIMIR PROFESSOR HACHINSKI In reality, vascular disease does not involve the and grow after the occurrence of stroke. brain to such an extent, and when dementia Similarly, inflammation is greater and flares. occurs it is often on the background of already Experimental treatment can suppress brain existing Alzheimer’s disease (AD). Thus, it is the changes and the cognitive consequences. co-occurrence and interaction of vascular disease and AD that is most commonly responsible for If we confirm this clinically, it will allow cognitive impairment in the elderly. Moreover, clinicians worldwide to use a joint the term vascular cognitive impairment can be treatment of anti-amyloid and anti- defined as any cognitive impairment caused by, or inflammatory agents to reduce the impact associated with, vascular factors. and mitigate the effects of stroke. It will also delay AD in those who might have This approach is promising as it emphasises become prone to it by the infarct. This has the one component that we can now treat and tremendous implications given that by the prevent, which is the vascular one. age of 73 around 50 per cent of the general population will have amyloid accumulations Another key area of your research is the within the brain. incidence of sudden death following stroke. Firstly, why does this occur, and secondly, why Our plans include a multidisciplinary attack are right-handed individuals more susceptible? on the problem.
    [Show full text]
  • Always Caring
    always caring 2006 REPORT TO THE COMMUNITY 1 3 London Health Sciences Centre (LHSC) is one of Canada’s largest acute care Message from the Chair of the Board of Directors page 1 teaching hospitals and is dedicated to excellence in patient care, teaching and research. 7 Message from the President and Chief Executive Officer page 3 LHSC has pioneered many national and international medical breakthroughs. Located in London, Ontario, LHSC encompasses three sites, South Street Hospital, University Message from the Chief of Staff page 7 Hospital and Victoria Hospital; two family medical centres; and the London Regional Message from the Chair of the Finance Committee page 9 Cancer Program. LHSC is the home of the Children’s Hospital of Western Ontario and CSTAR (Canadian Surgical Technologies & Advanced Robotics). The research arm 2005/2006 Activities and Statistics page 11 of LHSC is Lawson Health Research Institute, which is partnered with London’s other teaching hospital, St. Joseph’s Health Care, London. LHSC is affiliated with The University Always Moving Forward of Western Ontario. Physicians and staff at LHSC number close to 9,000 and together • June 12 hospital move page 13 9 they provided care for more than one million patient visits last year. Always Caring • New trauma unit puts patients at centre page 17 • Hospital researchers awarded major page 20 funding for breast cancer research • New program shortens hospital page 21 stay for hip and knee replacements 13 Always Innovating • Leading the way in diagnostic advancements page 22 • BRAINSAVE uses technology, partnerships page 24 to improve stroke treatment • Robotic assisted cardiac surgery is first in the world page 24 • Historic digital imaging network project page 25 brings care closer to home 17 Medical Breakthroughs page 26 On the cover: Nurse Sheila Ford cares for a patient in the new Critical Care Trauma Centre at LHSC Victoria Hospital.
    [Show full text]
  • Printable List of Laureates
    Laureates of the Canadian Medical Hall of Fame A E Maude Abbott MD* (1994) Connie J. Eaves PhD (2019) Albert Aguayo MD(2011) John Evans MD* (2000) Oswald Avery MD (2004) F B Ray Farquharson MD* (1998) Elizabeth Bagshaw MD* (2007) Hon. Sylvia Fedoruk MA* (2009) Sir Frederick Banting MD* (1994) William Feindel MD PhD* (2003) Henry Barnett MD* (1995) B. Brett Finlay PhD (2018) Murray Barr MD* (1998) C. Miller Fisher MD* (1998) Charles Beer PhD* (1997) James FitzGerald MD PhD* (2004) Bernard Belleau PhD* (2000) Claude Fortier MD* (1998) Philip B. Berger MD (2018) Terry Fox* (2012) Michel G. Bergeron MD (2017) Armand Frappier MD* (2012) Alan Bernstein PhD (2015) Clarke Fraser MD PhD* (2012) Charles H. Best MD PhD* (1994) Henry Friesen MD (2001) Norman Bethune MD* (1998) John Bienenstock MD (2011) G Wilfred G. Bigelow MD* (1997) William Gallie MD* (2001) Michael Bliss PhD* (2016) Jacques Genest MD* (1994) Roberta Bondar MD PhD (1998) Gustave Gingras MD* (1998) John Bradley MD* (2001) Phil Gold MD PhD (2010) Henri Breault MD* (1997) Richard G. Goldbloom MD (2017) G. Malcolm Brown PhD* (2000) Jean Gray MD (2020) John Symonds Lyon Browne MD PhD* (1994) Wilfred Grenfell MD* (1997) Alan Burton PhD* (2010) Gordon Guyatt MD (2016) C H G. Brock Chisholm MD (2019) Vladimir Hachinski MD (2018) Harvey Max Chochnov, MD PhD (2020) Antoine Hakim MD PhD (2013) Bruce Chown MD* (1995) Justice Emmett Hall* (2017) Michel Chrétien MD (2017) Judith G. Hall MD (2015) William A. Cochrane MD* (2010) Michael R. Hayden MD PhD (2017) May Cohen MD (2016) Donald O.
    [Show full text]
  • Saved Lives of Colleagues, Friends, and Patients, Or at Least Prevented Forced Sterilizations
    HISTORICAL REVIEW Neuroscience in Nazi Europe Part II: Resistance against the Third Reich Lawrence A. Zeidman ABSTRACT: Previously, I mentioned that not all neuroscientists collaborated with the Nazis, who from 1933 to 1945 tried to eliminate neurologic and psychiatric disease from the gene pool. Oskar and Cécile Vogt openly resisted and courageous ly protested against the Nazi regime and its policies, and have been discussed previously in the neurology literature. Here I discuss Alexander Mitscherlich, Haakon Saethre, Walther Spielmeyer, Jules Tinel, and Johannes Pompe. Other neuroscientists had ambivalent roles, including Hans Creutzfeldt, who has been discussed previously. Here, I discuss Max Nonne, Karl Bonhoeffer, and Oswald Bumke. The neuroscientists who resisted had different backgrounds and moti vations that likely influenced their behavior, but this group undoubtedly saved lives of colleagues, friends, and patients, or at least prevented forced sterilizations. By recognizing and understanding the actions of these heroes of neuroscience, we pay homage and realize how ethics and morals do not need to be compromised even in dark times. RÉSUMÉ: Neuroscience en Europe sous domination nazie, 2e partie : résistance contre le Troisième Reich. J’ai mentionné antéri eurement que tous les neuroscientifiques n’avaient pas collaboré avec les nazis qui, de 1933 à 1945, ont tenté d’éliminer la maladie neurologique et psychiatrique du patrimoine génétique. Oskar et Cécile Vogt se sont opposés ouvertement et ont protesté courageusement contre le régime nazi et ses politiques. Ce sujet a déjà été exposé dans la littérature neurologique. Je discute ici d’Alexander Mitscherlich, de Haakon Saethre, de Walther Spielmeyer, de Jules Tinel et de Johannes Pompe.
    [Show full text]
  • Dean's Report 2013
    The DEAN’S REPORT SCHULICH SCHOOL OF MEDICINE & DENTISTRY ANNUAL PERFORMANCE REVIEW | 2013 CONTENTS 03 A Message from Dr. Michael J. Strong 05 OPERATIONS & ADMINISTRATION 07 Space and Facilities 08 Finance 09 Human Resources 13 Alumni Relations and Development 15 OUTSTANDING EDUCATION 17 Program Offerings 18 Doctor of Medicine Program 20 Doctor of Medicine – Windsor Program 21 Distributed Medical Education 22 Postgraduate Medical Education 23 Doctor of Dental Surgery 26 Internationally Trained Dentists 27 Bachelor of Medical Sciences and Undergraduate Program in Neuroscience 29 Graduate and Postdoctoral Studies Office 30 Clinical Graduate Programs 31 Combined Degree Programs 33 CIHR Strategic Training Programs 34 Centre for Education Research & Innovation 35 Clinical Skills Learning Program 36 Continuing Professional Development 37 FINANCIAL ACCESSIBILITY 39 Scholarships, Awards and Bursaries 41 RESEARCH 43 Research Highlights 44 Research Funding 45 Notable Research Publications 46 Canada Research Chairs 47 Robarts Research Institute 49 AWARDS 59 INTERNATIONAL EFFORTS 63 SOCIAL RESPONSIBILITY THE DEAN’S REPORT | 2013 2 A MESSAGE FROM A MESSAGE FROM DR. MICHAEL J. STRONG 3 THE DEAN’S REPORT | 2013 The past year at the Schulich School of Medicine & Dentistry was one of action and celebration. Collectively, our School’s faculty and staff rolled up their sleeves to tackle some of the biggest initiatives and goals mapped out in our Strategic Plan. It was exciting and energizing to witness the plans come to fruition, and to celebrate our accomplishments which support our vision to become a global leader in optimizing life-long health through innovations in research, education and active engagement with our communities. The successful launch of our Master of Public Health Program was a major achievement for our School.
    [Show full text]